C5 and paroxysmal nocturnal hemoglobinuria: Another study using Soliris (Eculizumab), an FDA-approved C5 inhibitor, for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) has shown that Eculizumab application in a septic child rescued the sepsis-induced multiorgan failure, including cardiac dysfunction (Galic et al., 2019).